Last reviewed · How we verify

Stem Cell Transplantation

Stem Cells Arabia · Phase 2 active Biologic ✓ Verified May 2026

Stem Cell Transplantation is a Biologic drug developed by Stem Cells Arabia. It is currently in Phase 2 development. Also known as: Autologous Bone marrow derived stem cell transplantation.

Stem cell transplantation is a medical treatment used to study conditions such as B-Cell Acute Lymphoblastic Leukemia, Constrictive Bronchiolitis, and Graft vs Host Disease, among others. The treatment involves interventions like blinatumomab combined with venetoclax as maintenance therapy, Cyclosporine Inhalation Solution, and Decitabine, which target the removal of necrotic tissue through enzymatic activity.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameStem Cell Transplantation
Also known asAutologous Bone marrow derived stem cell transplantation
SponsorStem Cells Arabia
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Stem Cell Transplantation

What is Stem Cell Transplantation?

Stem Cell Transplantation is a Biologic drug developed by Stem Cells Arabia.

Who makes Stem Cell Transplantation?

Stem Cell Transplantation is developed by Stem Cells Arabia (see full Stem Cells Arabia pipeline at /company/stem-cells-arabia).

Is Stem Cell Transplantation also known as anything else?

Stem Cell Transplantation is also known as Autologous Bone marrow derived stem cell transplantation.

What development phase is Stem Cell Transplantation in?

Stem Cell Transplantation is in Phase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing